Rethinking typhoid fever vaccines: Implications for travelers and people living in highly endemic areas

Journal of Travel Medicine

Volumn 16, Issue 1, 2009, Pages 46-52

  Whitaker, Jennifer A ^a   Franco Paredes, Carlos ^a   Del Rio, Carlos ^a   Edupuganti, Srilatha ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATOVAQUONE PLUS PROGUANIL; CHLOROQUINE; IMMUNOGLOBULIN G ANTIBODY; LIVE VACCINE; MEFLOQUINE; O ANTIGEN; PRIMAQUINE; TYPHOID VACCINE;

BACTERIAL STRAIN; ENDEMIC DISEASE; GEOGRAPHIC DISTRIBUTION; HUMAN; IMMUNIZATION; IMMUNOGENICITY; INCIDENCE; REVIEW; SALMONELLA ENTERICA; SALMONELLA PARATYPHI; SALMONELLA TYPHI; TRAVEL; TYPHOID FEVER;

HUMANS; MASS IMMUNIZATION; PARATYPHOID FEVER; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SALMONELLA ENTERICA; SALMONELLA TYPHI; TRAVEL; TYPHOID FEVER; TYPHOID-PARATYPHOID VACCINES;

EID: 58449135850     PISSN: 11951982     EISSN: 17088305     Source Type: Journal    
DOI: 10.1111/j.1708-8305.2008.00273.x     Document Type: Review

References (74)

1. Crump JA, Luby SP, Mintz ED. The global burden of typhoid fever. Bull World Health Organ 2004 82 : 346 353.
2. Sinha A, Sazawal S, Kumar R, et al. Typhoid fever in children aged less than 5 years. Lancet 1999 354 : 734 737.
3. Lin FY, Vo AH, Phan VB, et al. The epidemiology of typhoid fever in the Dong Thap Province, Mekong Delta region of Vietnam. Am J Trop Med Hyg 2000 62 : 644 648.
4. Ferreccio C, Levine MM, Manterola A, et al. Benign bacteremia caused by Salmonella typhi and paratyphi in children younger than 2 years. J Pediatr 1984 104 : 899 901.
5. Parry CM, Hoa NT, Diep TS, et al. Value of a single-tube widal test in diagnosis of typhoid fever in Vietnam. J Clin Microbiol 1999 37 : 2882 2886.
6. Stuart BM, Pullen RL. Typhoid: clinical analysis of three hundred and sixty cases. Arch Intern Med 1946 78 : 629 661.
7. Ivanoff B, Levine MM, Lambert PH. Vaccination against typhoid fever: present status. Bull World Health Organ 1994 72 : 957 971.
8. Vollaard AM, Ali S, Widjaja S, et al. Identification of typhoid fever and paratyphoid fever cases at presentation in outpatient clinics in Jakarta, Indonesia. Trans R Soc Trop Med Hyg 2005 99 : 440 450.
9. Maskey AP, Day JN, Phung QT, et al. Salmonella enterica serovar Paratyphi A and S. enterica serovar Typhi cause indistinguishable clinical syndromes in Kathmandu, Nepal. Clin Infect Dis 2006 42 : 1247 1253.
10. Meltzer E, Sadik C, Schwartz E. Enteric fever in Israeli travelers: a nationwide study. J Travel Med 2005 12 : 275 281.
11. Woods CW, Murdoch DR, Zimmerman MD, et al. Emergence of Salmonella enterica serotype Paratyphi A as a major cause of enteric fever in Kathmandu, Nepal. Trans R Soc Trop Med Hyg 2006 100 : 1063 1067.
12. Tankhiwale SS, Agrawal G, Jalgaonkar SV. An unusually high occurrence of Salmonella enterica serotype paratyphi A in patients with enteric fever. Indian J Med Res 2003 117 : 10 12.
13. Sood S, Kapil A, Dash N, et al. Paratyphoid fever in India: an emerging problem. Emerg Infect Dis 1999 5 : 483 484.
14. Ochiai RL, Wang X, von Seidlein L, et al. Salmonella paratyphi A rates, Asia. Emerg Infect Dis 2005 11 : 1764 1766.
15. Murdoch DR, Woods CW, Zimmerman MD, et al. The etiology of febrile illness in adults presenting to Patan hospital in Kathmandu, Nepal. Am J Trop Med Hyg 2004 70 : 670 675.
16. Steinberg EB, Bishop R, Haber P, et al. Typhoid fever in travelers: who should be targeted for prevention? Clin Infect Dis 2004 39 : 186 191.
17. Ackers ML, Puhr ND, Tauxe RV, Mintz ED. Laboratory-based surveillance of Salmonella serotype Typhi infections in the United States: antimicrobial resistance on the rise. JAMA 2000 283 : 2668 2673.
18. Mermin JH, Townes JM, Gerber M, et al. Typhoid fever in the United States, 1985-1994: changing risks of international travel and increasing antimicrobial resistance. Arch Intern Med 1998 158 : 633 638.
19. Lighton LL. Follow up in north west England of cases of enteric fever acquired abroad, April 1996 to March 1998. Commun Dis Public Health 1999 2 : 145 146.
20. Ekdahl K, de Jong B, Andersson Y. Risk of travel-associated typhoid and paratyphoid fevers in various regions. J Travel Med 2005 12 : 197 204.
21. Health Protection Agency. Salmonella Typhi and Salmonella Paratyphi laboratory reports (cases only) reported to the health protection agency centre for infections England and Wales, 1980-2006. Health Protection Agency. Available at : http://www.hpa.org.uk/infections/topics-az/salmonella/data-typh.htm Accessed 2008 Dec 1)
22. Parry C, Wain J, Chinh NT, et al. Quinolone-resistant Salmonella typhi in Vietnam. Lancet 1998 351 : 1289.
23. Murdoch DA, Banatvaia N, Bone A, et al. Epidemic ciprofloxacin-resistant Salmonella typhi in Tajikistan. Lancet 1998 351 : 339.
24. Mirza SH, Beeching NJ, Hart CA. Multi-drug resistant typhoid: a global problem. J Med Microbiol 1996 44 : 317 319.
25. Safdar A, Kaur H, Elting L, Rolston K. Antimicrobial susceptibility of 128 Salmonella enterica serovar typhi and paratyphi A isolates from northern India. Chemotherapy 2004 50 : 88 91.
26. Rowe B, Ward LR, Threlfall EJ. Multidrug-resistant Salmonella typhi: a worldwide epidemic. Clin Infect Dis 1997 24 (Suppl 1 S106 S109.
27. Rowe B, Ward LR, Threlfall EJ. Ciprofloxacin-resistant Salmonella typhi in the UK. Lancet 1995 346 : 1302.
28. Hampton MD, Ward LR, Rowe B, Threlfall EJ. Molecular fingerprinting of multidrug-resistant Salmonella enterica serotype Typhi. Emerg Infect Dis 1998 4 : 317 320.
29. Gupta A. Multidrug-resistant typhoid fever in children: epidemiology and therapeutic approach. Pediatr Infect Dis J 1994 13 : 134 140.
30. Arya SC, Sharma KB. Urgent need for effective vaccine against Salmonella paratyphi A, B and C. Vaccine 1995 13 : 1727 1728.
31. Germanier R, Füer E. Isolation and characterization of Gal E mutant Ty 21a of Salmonella typhi: a candidate strain for a live, oral typhoid vaccine. J Infect Dis 1975 131 : 553 558.
32. Levine MM. Typhoid fever vaccines. In : Plotkin SA, Orenstein WA, eds. Vaccines. 4th Ed. Philadelphia : Saunders, 2004 : 1057 1093.
33. Sztein MB. Cell-mediated immunity and antibody responses elicited by attenuated Salmonella enterica Serovar Typhi strains used as live oral vaccines in humans. Clin Infect Dis 2007 45 (Suppl 1 S15 S19.
34. Guzman CA, Borsutzky S, Griot-Wenk M, et al. Vaccines against typhoid fever. Vaccine 2006 24 : 3804 3811.
35. Ferreccio C, Levine MM, Rodriguez H, Contreras R. Comparative efficacy of two, three, or four doses of TY21a live oral typhoid vaccine in enteric-coated capsules: a field trial in an endemic area. J Infect Dis 1989 159 : 766 769.
36. Fraser A, Goldberb E, Acosta CJ, et al. Vaccines for preventing typhoid fever. Cochrane Database Syst Rev 2007 : CD001261. doi: 10.1002/14651858. CD001261.pub2 A, Paul M, Goldberg E, et al. Typhoid fever vaccines: systematic review and meta-analysis of randomised controlled trials. Vaccine 2007 25 : 7848 7857.
37. Typhoid vaccines: WHO position paper. Wkly Epidemiol Rec 2008 83 : 49 59.
38. Marcus LC, Froeschle JE, Hill DR, et al. Safety of Typhim Vi vaccine in a postmarketing observational study. J Travel Med 2007 14 : 386 391.
39. Garmory HS. Salmonella vaccines for use in humans: present and future perspectives. FEMS Microbiol Rev 2002 26 : 339 353.
40. Levine MM, Ferreccio C, Black RE, et al. Ty21a live oral typhoid vaccine and prevention of paratyphoid fever caused by Salmonella enterica Serovar Paratyphi B. Clin Infect Dis 2007 45 (Suppl 1 S24 S28.
41. Wahdan MH, Serie C, Cerisier Y, et al. A controlled field trial of live Salmonella typhi strain Ty 21a oral vaccine against typhoid: three-year results. J Infect Dis 1982 145 : 292 295.
42. Levine MM, Ferreccio C, Black RE, Germanier R. Large-scale field trial of Ty21a live oral typhoid vaccine in enteric-coated capsule formation. Lancet 1987 329 : 1049 1052.
43. Levine MM, Ferreccio C, Cryz S, Ortiz E. Comparison of enteric-coated capsules and liquid formulation of Ty21a typhoid vaccine in randomised controlled field trial. Lancet 1990 336 : 891 894.
44. Black RE, Levine MM, Ferreccio C, et al. Efficacy of one or two doses of Ty21a Salmonella typhi vaccine in enteric-coated capsules in a controlled field trial. Chilean Typhoid Committee. Vaccine 1990 8 : 81 84.
45. Simanjuntak CH, Paleologo FP, Punjabi NH, et al. Oral immunisation against typhoid fever in Indonesia with Ty21a vaccine. Lancet 1991 338 : 1055 1059.
46. Acharya IL, Lowe CU, Thapa R, et al. Prevention of typhoid fever in Nepal with the Vi capsular polysaccharide of Salmonella typhi. A preliminary report. N Engl J Med 1987 317 : 1101 1104.
47. Klugman KP, Koornhof HJ, Robbins JB, Le Cam NN. Immunogenicity, efficacy and serological correlate of protection of Salmonella typhi Vi capsular polysaccharide vaccine three years after immunization. Vaccine 1996 14 : 435 438.
48. Klugman KP, Gilbertson IT, Koornhof HJ, et al. Protective activity of Vi capsular polysaccharide vaccine against typhoid fever. Lancet 1987 2 : 1165 1169.
49. Fraser A, Goldberg E, Acosta CJ, et al. Vaccines for preventing typhoid fever update of Cochrane Database Syst Rev 2000;2:CD001261]. Cochrane Database of Syst Rev 2007 3 : CD001261.
50. Engels EA, Falagas ME, Lau J, Bennish ML. Typhoid fever vaccines: a meta-analysis of studies on efficacy and toxicity. BMJ 1998 316 : 110 116.
51. Plotkin SA, Aubin F, Robbins J. Meta-analysis of typhoid vaccine efficacy trials showed that whole cell vaccines are more effective than either the oral, attenuated vaccine or the Vi polysaccharide vaccine. Vaccine 1999 17 : 2763.
52. Engels EA, Bennish ML, Falagas ME, Lau J. Typhoid fever vaccines. Vaccine 2000 18 : 1433 1434.
53. Clemens J, Hoffman S, Ivanoff B, et al. Typhoid fever vaccines. Vaccine 1999 17 : 2476 2478.
54. Hornick RB, Woodward TE, McCrumb FR, et al. Typhoid fever vaccine-yes or no? Med Clin North Am 1967 51 : 617 623.
55. Initiative for Vaccine Research. Typhoid fever. WHO. 2008. Available at : http://www.who.int/vaccine-research/diseases/diarrhoeal/en/index7.html Accessed 2008 Aug 27)
56. Lin FY, Ho VA, Khiem HB, et al. The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children. N Engl J Med 2001 344 : 1263 1269.
57. Kirkpatrick BD, Tenney KM, Larsson CJ, et al. The novel oral typhoid vaccine M01ZH09 is well tolerated and highly immunogenic in 2 vaccine presentations (see comment). J Infect Dis 2005 192 : 360 366.
58. Tacket CO, Levine MM. CVD 908, CVD 908-htrA, and CVD 909 live oral typhoid vaccines: a logical progression. Clin Infect Dis 2007 45 (Suppl 1 S20 S23.
59. Hohmann EL, Oletta CA, Killeen KP, Miller SI. phoP/phoQ-deleted Salmonella typhi (Ty800) is a safe and immunogenic single-dose typhoid fever vaccine in volunteers. J Infect Dis 1996 173 : 1408 1414.
60. Lee HY, Cho SA, Lee IS, et al. Evaluation of phoP and rpoS mutants of Salmonella enterica serovar Typhi as attenuated typhoid vaccine candidates: virulence and protective immune responses in intranasally immunized mice. FEMS Immunol Med Microbiol 2007 51 : 310 318.
61. Kozicki M, Steffen R, Cheer M. "Boil it, cook it, peel it, or forget it": does this rule prevent traveller's diarrhoea? Int J Infect Dis 1985 14 : 169 172.
62. Papadimitropoulos V, Vergidis PI, Bliziotis I, Falagas ME. Vaccination against typhoid fever in travellers: a cost-effectiveness approach. Clin Microbiol Infect 2004 10 : 681 683.
63. Behrens RH, Roberts JA. Is travel prophylaxis worth while? Economic appraisal of prophylactic measures against malaria, hepatitis A, and typhoid in travellers. BMJ 1994 309 : 918 922.
64. Cobelens FG, Kooij S, Warris-Versteegen A, Visser LG. Typhoid fever in group travelers: opportunity for studying vaccine efficacy. J Travel Med 2000 7 : 19 24.
65. Ochiai RL, Acosta CJ, Agtini M, et al. The use of typhoid vaccines in Asia: the DOMI experience. Clin Infect Dis 2007 45 (Suppl 1 S34 S38.
66. Bodhidatta L, Taylor DN, Thisyakorn U, Echeverria P. Control of typhoid fever in Bangkok, Thailand, by annual immunization of schoolchildren with parenteral typhoid vaccine. Rev Infect Dis 1987 9 : 841 845.
67. DeRoeck D, Jodar L, Clemens J. Putting typhoid vaccination on the global health agenda. N Engl J Med 2007 357 : 1069 1071.
68. Yang J, Acosta CJ, Si GA, et al. A mass vaccination campaign targeting adults and children to prevent typhoid fever in Hechi; expanding the use of Vi polysaccharide vaccine in southeast China: a cluster-randomized trial. BMC Public Health 2005 5 : 49.
69. Agtini MD, Ochiai RL, Soeharno R, et al. Introducing Vi polysaccharide typhoid fever vaccine to primary school children in North Jakarta, Indonesia, via an existent school-based vaccination platform. Public Health 2006 120 : 1081 1087.
70. Khan MI, Ochiai RL, Hamsa HB, et al. Lessons and implications from a mass immunization campaign in squatter settlements of Karachi, Pakistan: an experience from a cluster-randomized double-blinded vaccine trial [NCT00125047]. Trials 2006 7 : 17.
71. Poulos C, Bahl R, Whittington D, et al. A cost-benefit analysis of typhoid fever immunization programmes in an Indian urban slum community. J Health Popul Nutr 2004 22 : 311 321.
72. Thiem VD, Danovaro-Holliday MC, Canh DG, et al. The feasibility of a school-based VI polysaccharide vaccine mass immunization campaign in Hue City, central Vietnam: streamlining a typhoid fever preventive strategy. Southeast Asian J Trop Med Public Health 2006 37 : 515 522.
73. Yang HH, Kilgore PE, Yang LH, et al. An outbreak of typhoid fever, Xing-an county, People's Republic of China, 1999: estimation of the field effectiveness of Vi polysaccharide typhoid vaccine. J Infect Dis 2001 : 183 : 1775 1780.
74. Tarr PE, Kuppens L, Jones TC, et al. Considerations regarding mass vaccination against typhoid fever as an adjunct to sanitation and public health measures: potential use in an epidemic in Tajikistan. Am J Trop Med Hyg 1999 61 : 163 170.